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The purpose is to demonstrate the ability to generate clinically acceptable prostate 
permanent seed implant plans using two seed types which are identical except for 
their activity. The IPSA inverse planning algorithms were modified to include mul-
tiple dose matrices for the calculation of dose from different sources, and a selection 
algorithm was implemented to allow for the swapping of source type at any given 
source position. Five previously treated patients with a range of  prostate volumes 
from 20–48 cm3 were re-optimized under two hybrid scenarios: (1) using 0.32 and 
0.51 mGy ⋅ m2 / h  125I, and (2) using 0.64 and 0.76 mGy ⋅ m2 / h 125I. Isodose lines 
were generated and dosimetric indices , V150
Prostate , D90
Prostate , V150
Urethra , V125
Urethra , V120
Urethra , 
V100
Urethra , and D10
Urethra  were calculated. The algorithm allows for the generation of 
single-isotope, multi-activity hybrid brachytherapy plans. By dealing with only one 
radionuclide, but of different activity, the biology is unchanged from a standard plan. 
All V100
Prostate  were within 2.3 percentage points for every plan and always above the 
clinically desirable 95%. All V150
Urethra  were identically zero, and V120
Urethra  is always 
below the clinically acceptable value of 1.0 cm3. Clinical optimization times for 
the hybrid plans are still under one minute, for most cases. It is possible to gener-
ate clinically advantageous brachytherapy plans (i.e. obtain the same quality dose 
distribution as a standard single-activity plan) while incorporating leftover seeds 
from a previous patient treatment. This method will allow a clinic to continue to 
provide excellent patient care, but at a reduced cost. Multi-activity hybrid plans 
were equal in quality (as measured by the standard dosimetric indices) to plans 
with seeds of a single activity. Despite the expanded search space, optimization 
times for these studies were still under two minutes on a modern day laptop and 
can be reduced to below one minute in a clinical setting. With the typical cost of 
a set of PPI seeds on the order of thousands of dollars, it is possible to reduce the 
cost of brachytherapy treatments by allowing for easier use of seeds left over from 
a previous patient or unused due to a cancelled treatment. 
PACS number:  87.55.D-, 87.55.Kd, 87.55.ne
Key words: brachytherapy, prostate cancer, hybrid plans, prostate permanent-seed 
implant (PPI), optimization, IPSA 
I. IntroductIon
Current permanent prostate implant brachytherapy (PPI) dose plans use one type of radioactive 
seed per treatment plan, all with the same activity. Radioactive seeds must be ordered from a 
vendor and used before the radioactivity dissipates. The half-life of one of the more common 
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radionuclides, 125I, is approximately 60 days; therefore, if the seeds are not used within one 
week, the activity will have decreased by approximately 10%. For seeds like 103Pd and 131Cs, 
with half lives of 17 and 10 days respectively, the decrease is even greater (Table 1). Thus, if a 
treatment is missed, seeds — and therefore money — are wasted. These seeds are not entirely 
unusable and may be used for a different patient by generating a plan using the partially-decayed 
activity†; however, this can only be done if there are enough seeds for an entire plan. 
Table 1. Half-lives for commonly-used PPI seeds: 0.76 mGy ⋅ m2  / h (0.6 mCi) 125I = 0.65 mGy ⋅ m2  / h (0.51 mCi) 
125I after two weeks.
 Seed Type  Half Life  Activity after
  7 days  14 days 
Iodine-125  59.9 days  92%  85% 
Palladium-103  17.0 days  75%  57% 
Cesium-131  9.7 days  62%  38%
In addition, it has been reported that it is important to account for differences in the seeds 
supplied by different manufacturers when generating treatment plans and calculating dosim-
etry. Identical plans using the same radionuclide but from different vendors will have different 
dosimetry due to different dose rate constants, anisotropy factors, and radial dose functions of 
each vendor’s seeds.(1,2,3) 
There has been recent interest in generating dose plans with two different radionuclides. 
In their 2002 paper on the feasibility of 192Ir seeds for PPI, Glasgow et al.(4) proposed that 
combinations of 192Ir and 125I seeds can provide adequate coverage of the prostate and spar-
ing of the organs at risk. In this case, the argument is that 192Ir and 125I have similar half lives 
(73.83 days verses 59.40 days) and similar absorbed doses delivered in the permanent implant. 
Therefore, the radiobiological effects of using two different radionuclides is negligible for cases 
which used up to 40 mGy ⋅ m2 / h (10 mCi) 192Ir. In 2007, Chaswal et al.(5) expanded on the 
forward planning-based work of Glasgow and used a Greedy Heuristic algorithm to optimize 
the treatment plans. They showed that there can be dosimetric and trauma-reducing benefits 
to using plans with a combination of 192Ir and 125I. These studies are promising in that they 
show a clinical benefit can be derived from including more than one radionuclide in a given 
brachytherapy plan. However, the results are dependent on knowing and understanding the 
biology of the superposition of two different radiation delivery mechanisms. 
There has been progress made recently in our understanding of the biological responses to 
different dose delivery characteristics of different radionuclides. In fact, some recent studies 
have shown no significant difference between biochemical failure and control as a function 
of biological equivalent dose (BED), equivalent uniform dose (EUD), or tumor control prob-
ability (TCP) when comparing plans using 125I and 103Pd.(6) However, even setting aside the 
uncertainty in CT-reconstructed target volumes, there is a lack of consensus about the actual 
value of the biological parameters that govern the definition of the BED, EUD, and TCP, with 
values of α/β differing by more than a factor of 2.(7) The uncertainty in the models that predict 
the biological effect of the specific characteristics naturally propagates to the dosimetry of 
brachytherapy plans that incorporate multiple radionuclides. 
However, assuming the uncertainty in the biology is acceptable, there does appear to be a 
benefit to using multiple types of seeds (each with a different dosimetry) in one brachytherapy 
plan.(4,5) In this work, we aim to avoid the biology-based uncertainties attached to the use of 
two different radionuclides. It would be beneficial to be able to generate clinically-acceptable 
† We use will use partial activity or fractional activity to describe a seed that has only a fraction of their original 
activity. Usually this is a seed that was not used immediately after ordering from a vendor (e.g. those left over 
from a cancelled treatment or from ordering too many seeds for a given implant).
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hybrid plans that incorporate seeds of the same radionuclide, but with different characteristics 
— be they different activity or slightly different dosimetric geometry. In contrast to plans using 
multiple radionuclides, single radionuclide hybrid plans are free from the biological uncertain-
ties associated with the efficacy combining characteristically different radiation. 
We present an algorithm that allows for the generation of single-isotope, multi-activity 
 hybrid brachytherapy plans. By dealing with only one radionuclide, but of different activity, it 
is possible to generate clinically advantageous brachytherapy plans: i.e. obtain the same  quality 
dose distribution as a standard single-activity plan while incorporating left over seeds from 
a previous patient treatment. This method will allow a clinic to continue to provide excellent 
patient care, but at a reduced cost. 
II. MAtErIALS And MEtHodS
A. code development rational 
The algorithms developed for this work augment the IPSA inverse planning algorithms.(8,9,10,11) 
While the core optimization engine remains unchanged, the code was modified in three ways: 
(1) more than one radionuclide source can be specified using the TG-43 formalism;(12) (2) the 
system for evaluating the dose delivered to the target and surrounding organs was expanded to 
incorporate two separate radionuclide dose profiles; and (3) the optimization engine can switch 
the seed type at each source position at specific moments during the iteration process. 
As in the original algorithm, to determine the dose, Dj, delivered to unit volume (voxel) j of 
an organ, the contributions from the ith source position, Dij, are summed: 
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Np is the number of source positions. The total dose, D, to an organ is the sum of the dose 
at each voxel within that organ, Nv is the number of voxels in the organ. 
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However, in the new algorithm, the dose matrix (Dij) used depends on which seed is  present 
at position i. During the initialization phase of the optimization process, the algorithm com-
putes a separate dose matrix for each seed type. Then an initial configuration of seeds is placed 
in the target. This configuration is random, but the user has the ability to specify a desired 
 number of each seed type. The user also has the ability to permanently set the seed type at any 
source position. 
The algorithm then proceeds to the iteration phase, during which the search space is probed 
by placing or removing seeds of either type at randomly selected source positions. The new 
configuration is then (1) evaluated to determine the value of the objective function‡, (2) compared 
to the best configuration yet attained, and (3) kept or rejected based on the result of No. 2. 
‡ As described in Lessard et al.,(8) Lessard and Pouliot,(9) Lessard(10) and Pouliot et al.,(11) the objective function 
is computed by assessing penalties to doses delivered to organs which are out of the range desired by 
the medical physicist. The objective function is the main criteria for evaluating plans during the 
optimization process.
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In order to maximize clinical relevance, the optimization parameters were chosen from the 
class solution developed in Lessard et al.(8) and Pouliot.(13) This class solution was shown to 
mimic an experienced dosimetrist by consistently producing dose plans equivalent (as measured 
by common dosimetric indices) to those created by a dosimetrist in our clinic. This allows for 
better isolation of the variables which control the use of partial-activity seeds in the optimiza-
tion. Two limits on the number of needles allowed per plan are included: a soft penalty and an 
upper limit. The soft penalty is a weight multiplied by the total number of needles and then 
added into the objective function of the optimization. The upper limit restricts the number of 
needles allowed in one implant. Throughout the studies in this paper, the upper limit is set to 
30. This is the limit our clinic imposes, since our clinical experience has led to the conventional 
wisdom that, as the number of needles in one implant approaches 30, the complications due to 
edema, erectile dysfunction and other trauma begin to have unacceptably deleterious effects 
on the post-treatment quality of life of the patient. On average our clinic uses 25 needles per 
treatment plan for a 40 cm3 prostate gland. 
B. dosimetric analysis 
The quality of the plans generated in this analysis will be graded using the standard dosimetric 
indices developed by the American Association of Physicists in Medicine (AAPM), the American 
Brachytherapy Society (ABS), and our clinic. For brachytherapy treatment of prostate cancer, 
Stock et al.(14) have demonstrated that the minimum dose delivered to at least 90% of the gland 
(D90
Prostate ) had a critical impact on the subsequent risk of prostate-specific antigen-diagnosed 
recurrence. The American Brachytherapy Society has published general guidelines for differ-
ent anatomical sites(15) that consist of a set of dose limit specifications. Our clinic incorporates 
these recommendations and imposes even stricter limits for the target coverage and urethra 
dose,(8) which have yielded reproducible results: mature five-year biochemical control rates 
of 96% (median follow-up 63 months) reported for 118 consecutive patients.(16)  Plan quality 
was evaluated by the UCSF clinical physicist with experience generating over 1500 plans. For 
the purposes of this study, the single-activity plans were considered the control sample against 
which the dosimetry of the multiple-activity plans was judged. The validity of the standard 
(single-activity) plans was examined and established in previous work.(8) 
B.1 Target dose coverage 
The target coverage was compared across plans by examining volume of the prostate 
receiving at least the prescription dose (V100
Prostate ), at least 150% of the prescription dose 
(V150
Prostate ), and the minimum dose that covers 90% of the prostate (D90
Prostate ). In general, we 
strive to achieve V100
Prostate  > 95% and V150
Prostate  < 65%. A V100
Prostate  above 95% ensures complete 
coverage of the target, but will encourage a value of D90
Prostate  10%–20% above the prescription dose. 
Because this is a not a post-implant dosimetry analysis, but rather a pre-implant dosimetry 
analysis, it is important to see the D90
Prostate  higher than the prescription dose by approximately 
this amount,(2,3) since the dosimetry generally sees a decrease in post-implant D90
Prostate with 
respect to the pre-implant D90
Prostate . 
B.2 Urethral dosimetry 
One of the most common side effects of prostate brachytherapy (urethral stricture) is caused 
by excessive dose delivered to the urethra. The urethral volume receiving at least 100%, 120%, 
125%, and 150% of the presection dose (V100
Urethra , V120
Urethra , V125
Urethra , and V150
Urethra , respectively) 
as well as the minimum dose delivered to 10% of the urethra (D10
Urethra ), can be used to monitor 
the dose delivered to the urethra. To adequately protect the urethra, we strive to obtain V125
Urethra  
< 1.0 cm3 and V120
Urethra  < 1.0 cm3. 
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c. Procedure 
Five previously treated patients with a range of prostate volumes from 20 to 48 cm3 were  chosen 
and reoptimized using the hybrid-activity optimization. Different clinics use different seed 
activities — 0.3–0.5 mCi and up to 0.7 mCi are common.(17) Since our clinic uses 0.39 mCi, 
we performed this work using two different sets of seed activity. Four studies were organized 
into two scenarios. Of course the work presented here should not be considered indicative of 
the clinical work done at any institution; since many factors go into generating plans, these 
studies were kept as general as possible. In Scenario I, we generate hybrid plans using 0.32 and 
0.51 mGy ⋅ m2  / h (0.25 and 0.40 mCi) 125I seeds (A/A0 = 62.5%). In Scenario II, we generate 
hybrid plans using 0.64 and 0.76 mGy ⋅ m2  / h (0.50 and 0.60 mCi) 125I seeds (A/A0 = 83.3%). 
Table 2 outlines the parameters of the studies performed.
For each study, five plan types were generated with a prescription dose of 144 Gy: 
• Uni-activity–full activity: Only one seed type (the full activity) is available to theoptimization 
• 30 partial activity: The optimization is requested to use 30 of the partial activity seeds plus 
any number of the full activity seeds 
• 60 partial activity: The optimization is requested to use 60 of the partial activity seeds plus 
any number of the full activity seeds 
• Uni-activity–partial activity: Only one seed (the partial activity) available to the optimization 
• Unrestricted mix (pure hybrid): Allow the optimization to employ any number of each 
seed type 
The soft needle penalty encourages the optimization to minimize the number of needles in 
addition to optimizing the dose distribution. For Study 1 in Scenario I and II, this needle penalty 
is set to the value used in our clinic. For Study 2 in Scenario I and II, this was removed and the 
optimization was run with no per-needle penalty. 
Table 2. A summary of the studies performed.  
 Study Air Kerma Rate Per-needle Penalty  Results Table
  125I (U)    
Scenario I; Study 1  0.32 & 0.51  On  Table 3 
Scenario I; Study 2  0.32 & 0.51  Off  Table 4 
Scenario II; Study 1  0.64 & 0.76  On  Table 5 
Scenario II; Study 2  0.64 & 0.76  Off  Table 6
For each study five plan types were generated 
III. rESuLtS 
The dosimetric results for Scenario I are presented in Tables 3 and 4, and a set of isodose 
lines are shown in Fig. 1. The same are presented for Scenario II in Tables 5 & 6 and Fig. 2. 
The number of seeds of each activity is listed along with the standard dosimetric indices for 
the prostate (V100
Prostate , V150
Prostate , and D90
Prostate ) and for the urethra (V100
Urethra , V120
Urethra , V125
Urethra , and 
D10
Urethra ). VUrethra150 is identically zero for all cases and is, therefore, not listed in the Tables.
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Table 3.  Scenario I; Study 1. Data showing five separate plans generated for each patient case. Plans were 
generated with: (1) only one seed activity available to the optimization, 0.51 U 125I; (2) a requested 30 seeds of 
0.32 U 125I activity plus any number of seeds of 0.51 U 125I; (3) a requested 60 seeds of 0.32 U 125I plus any number of 
seeds of 0.51 U 125I; (4) only 0.32 U 125I seeds available to the optimization; (5) an unrestricted hybrid mix of 0.32 and 
0.51 U 125I. Per-needle penalty is on.
 Target Plan # of Total Low V100
Prostate
 V150
Prostate
 D90
Prostate
 D100
Urethra
 V120
Urethra
 V125
Urethra
 D10
Urethra
 Volume Type Needles Seeds Act. (%) (%) (Gy) (cm3) (cm3) (cm3) (Gy) 
 (cm3)    #(%)     
 48 Only 26 85 0(0) 96.9 64.0 178 0.6 0.4 0.1 184
  0.51 U
 48 30 29 94 28(30) 99.2 56.4 174 0.6 0.1 0.1 184
  0.32 U
 48 60 29 105 57(54) 98.2 59.6 178 0.6 0.2 0.1 186
  0.32 U
 48 Only 30 130 130(100) 98.6 57.2 178 0.6 0.3 0.1 186
  0.32 U
 48 Pure hybrid 29 94 24(26) 98.2 57.3 180 0.6 0.1 0.0 177
 47 Only 23 89 0(0) 99.4 61.4 179 0.8 0.1 0.0 174
  0.51 U
 47 30 26 100 30(30) 99.6 59.5 173 0.8 0.1 0.0 171
  0.32 U
 47 60 26 109 58(53) 99.2 59.3 175 0.8 0.1 0.0 175
  0.32 U
 47 Only 30 137 137(100) 98.8 61.9 175 0.9 0.1 0.0 175
  0.32 U
 47 Pure hybrid 25 100 32(32) 97.6 60.2 173 0.8 0.1 0.0 173
 36 Only 28 73 0(0) 96.6 63.9 173 0.5 0.1 0.0 177
  0.51 U
 36 30 30 85 30(35) 97.3 63.7 181 0.5 0.1 0.0 177
  0.32 U
 36 60 30 94 58(62) 98.2 62.0 176 0.5 0.0 0.0 173
  0.32 U
 36 Only 39 111 111(100) 97.6 59.8 176 0.6 0.0 0.0 173
  0.32 U
 36 Pure hybrid 28 82 25(30) 97.1 61.6 178 0.5 0.1 0.0 178
 29 Only 22 63 0(0) 98.2 62.7 178 0.9 0.2 0.0 178
  0.51 U
 29 30 25 74 29(39) 98.0 61.5 180 0.8 0.2 0.0 177
  0.32 U
 29 60 30 85 59(69) 97.9 61.6 176 0.8 0.2 0.0 177
  0.32 U
 29 Only 30 97 97(100) 97.4 56.7 176 0.8 0.0 0.0 177
  0.32 U
 29 Pure hybrid 25 71 22(31) 97.8 58.7 177 0.9 0.0 0.0 174
 20 Only 18 47 0(0) 96.9 64.7 175 0.4 0.2 0.2 189
  0.51 U
 20 30 18 57 29(51) 96.6 62.3 174 0.4 0.2 0.1 183
  0.32 U
 20 60 22 66 57(86) 96.7 64.1 173 0.4 0.2 0.1 188
  0.32 U
 20 Only 22 70 70(100) 97.3 62.7 173 0.4 0.2 0.1 188
  0.32 U
 20 Pure hybrid 19 51 12(24) 96.7 60.4 175 0.4 0.2 0.1 184
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Table 4. Scenario I; Study 2. Data showing five separate plans generated for each patient case. Plans were 
generated with: (1) only one seed activity available to the optimization, 0.51 U 125I; (2) a requested 30 seeds of 
0.32 U 125I activity plus any number of seeds of 0.51 U 125I; (3) a requested 60 seeds of 0.32 U 125I plus any number of 
seeds of 0.51 U 125I; (4) only one seed activity available, 0.32 U 125I; (5) unrestricted hybrid mix of 0.32 U and 
0.51 U 125I. Per-needle penalty is off.
 Target Plan # of Total Low V100
Prostate
 V150
Prostate
 D90
Prostate
 D100
Urethra
 V120
Urethra
 V125
Urethra
 D10
Urethra
 Volume Type Needles Seeds Act. (%) (%) (Gy) (cm3) (cm3) (cm3) (Gy) 
 (cm3)    #(%)     
 48 Only 30 86 0(0) 97.9 63.9 179 0.6 0.3 0.1 183
  0.51 U
 48 30 30 97 30(31) 99.0 56.2 181 0.6 0.1 0.0 176
  0.32 U
 48 60 30 105 58(55) 99.0 58.6 179 0.6 0.2 0.1 181
  0.32 U
 48 Only 30 129 129(100) 99.1 54.1 179 0.6 0.2 0.0 181
  0.32 U
 48 Pure hybrid 30 96 29(30) 99.3 56.5 180 0.6 0.1 0.0 178
 47 Only 29 88 0(0) 99.4 62.4 178 0.8 0.1 0.0 176
  0.51 U
 47 30 30 100 30(30) 99.6 60.5 173 0.8 0.0 0.0 173
  0.32 U
 47 60 30 110 60(55) 98.5 58.8 171 0.8 0.1 0.0 175
  0.32 U
 47 Only 30 136 136(100) 99.3 61.0 171 0.9 0.1 0.0 175
  0.32 U
 47 Pure hybrid 29 100 29(29) 99.0 57.1 176 0.8 0.1 0.0 174
 36 Only 30 74 0(0) 96.9 63.5 173 0.6 0.0 0.0 174
  0.51 U
 36 30 30 85 29(34) 97.5 61.4 179 0.5 0.1 0.0 176
  0.32 U
 36 60 30 95 59(62) 98.2 61.2 176 0.6 0.0 0.0 174
  0.32 U
 36 Only 30 111 111(100) 98.2 59.3 176 0.6 0.1 0.0 174
  0.32 U
 36 Pure hybrid 30 85 31(36) 96.7 60.8 178 0.5 0.1 0.0 175
 29 Only 29 64 0(0) 97.7 62.7 178 0.8 0.1 0.0 176
  0.51 U
 29 30 30 74 29(39) 97.9 59.6 179 0.8 0.1 0.0 173
  0.32 U
 29 60 30 85 60(71) 98.9 62.3 175 0.9 0.1 0.0 173
  0.32 U
 29 Only 30 96 96(100) 97.7 59.0 175 0.9 0.0 0.0 173
  0.32 U
 29 Pure hybrid 29 75 31(41) 97.9 59.4 176 0.8 0.0 0.0 172
 20 Only 19 47 0(0) 97.6 66.6 182 0.4 0.2 0.2 194
  0.51 U
 20 30 22 68 30(52) 97.6 63.7 179 0.4 0.2 0.1 183
  0.32 U
 20 60 24 66 57(86) 96.9 64.7 175 0.4 0.2 0.2 189
  0.32 U
 20 Only 25 71 71(100) 96.9 63.8 175 0.4 0.2 0.1 189
  0.32 U
 20 Pure hybrid 21 53 16(30) 96.4 62.1 177 0.4 0.2 0.0 180
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Fig. 1. Scenario I, Study 1: Isodose lines for one slice of the 48 cm3 prostrate. Isodose lines (outside in) are 50% (purple), 
100% (red), 125% (orange), 150% (yellow), 150% (black).  
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Table 5. Scenario II; Study 1. Data showing five separate plans generated for each patient case. Plans were 
generated with: (1) only one seed activity available to the optimization, 0.76 U 125I; (2) a requested 30 seeds of 
0.64 U 125I activity plus any number of seeds of 0.60 mCi 125I; (3) a requested 60 seeds of 0.64 U 125I plus any number of 
seeds of 0.76 U 125I; (4) only 0.64 U 125I seeds available to the optimization; (5) an unrestricted hybrid mix of 0.64 and 
0.76 U 125I. Per-needle penalty is on.
 Target Plan # of Total Low V100
Prostate
 V150
Prostate
 D90
Prostate
 D100
Urethra
 V120
Urethra
 V125
Urethra
 D10
Urethra
 Volume Type Needles Seeds Act. (%) (%) (Gy) (cm3) (cm3) (cm3) (Gy) 
 (cm3)    #(%)     
 48 Only 22 58 0(0) 98.6 50.3 174 0.6 0.2 0.0 179
  0.76 U
 48 30 23 62 29(47) 99.3 50.9 172 0.6 0.1 0.1 181
  0.64 U
 48 60 23 68 60(88) 98.4 53.8 178 0.7 0.2 0.1 183
  0.64 U
 48 Only 25 69 69(100) 99.6 57.0 178 0.7 0.1 0.1 183
  0.64 U
 48 Pure hybrid 23 63 33(52) 99.1 56.0 177 0.6 0.1 0.1 181
 47 Only 28 61 0(0) 98.7 59.9 169 0.9 0.1 0.0 173
  0.76 U
 47 30 30 65 30(46) 98.0 56.8 175 0.8 0.1 0.0 175
  0.64 U
 47 60 29 70 59(84) 98.5 62.4 175 0.8 0.1 0.0 176
  0.64 U
 47 Only 28 72 72(100) 96.9 56.9 175 0.8 0.1 0.0 176
  0.64 U
 47 Pure hybrid 28 65 33(51) 98.2 57.1 171 0.8 0.0 0.0 172
 36 Only 28 51 0(0) 96.9 57.7 176 0.5 0.2 0.2 186
  0.76 U
 36 30 29 55 29(53) 95.7 56.4 178 0.5 0.1 0.0 178
  0.64 U
 36 60 28 60 59(98) 96.1 60.1 176 0.5 0.1 0.0 175
  0.64 U
 36 Only 28 60 60(100) 97.0 58.4 176 0.5 0.2 0.0 175
  0.64 U
 36 Pure hybrid 30 55 28(51) 96.3 58.0 180 0.5 0.2 0.0 179
 29 Only 26 43 0(0) 97.3 57.6 177 0.8 0.2 0.0 177
  0.76 U
 29 30 25 48 29(60) 96.5 53.9 174 0.7 0.0 0.0 171
  0.64 U
 29 60 26 52 52(100) 97.6 58.5 179 0.7 0.1 0.0 176
  0.64 U
 29 Only 28 52 52(100) 97.0 57.1 179 0.9 0.0 0.0 176
  0.64 U
 29 Pure hybrid 27 47 19(40) 97.9 53.3 179 0.8 0.0 0.0 172
 20 Only 17 32 0(0) 94.7 62.0 172 0.4 0.2 0.1 185
  0.76 U
 20 30 18 37 29(78) 97.3 58.8 173 0.4 0.2 0.0 181
  0.64 U
 20 60 18 39 39(100) 94.7 62.0 172 0.4 0.2 0.1 185
  0.64 U
 20 Only 18 39 39(100) 93.7 59.6 172 0.4 0.2 0.1 185
  0.64 U
 20 Pure hybrid 18 35 17(49) 95.1 56.1 171 0.4 0.2 0.0 181
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Table 6. Scenario II; Study 2. Study of 0.635 U vs. 0.6 mCi and hybrid plans. Data showing five separate plans 
generated for each patient case – Prostate dosimetric indices. Plans were generated with: (1) only one seed activity 
available to the optimization, 0.76 U 125I; (2) a requested 30 seeds of 0.64 U 125I activity plus any number of seeds of 
0.60 mCi 125I; (3) a requested 60 seeds of 0.64 U 125I plus any number of seeds of 0.76 U 125I; (4) only 0.64 U 125I seeds 
available to the optimization; (5) an unrestricted hybrid mix of 0.64 and 0.76 U 125I. Per-needle penalty off.
 Target Plan # of Total Low V100
Prostate
 V150
Prostate
 D90
Prostate
 D100
Urethra
 V120
Urethra
 V125
Urethra
 D10
Urethra
 Volume Type Needles Seeds Act. (%) (%) (Gy) (cm3) (cm3) (cm3) (Gy) 
 (cm3)    #(%)     
 48 Only 30 57 0(0) 99.3 52.6 177 0.6 0.1 0.0 181
  0.76 U
 48 30  30 62 29(47) 99.3 46.2 173 0.6 0.1 0.1 181
  0.64 U 
 48 60 30 68 60(88) 99.0 56.7 180 0.6 0.1 0.0 177
  0.64 U
 48 Only 30 69 69(100) 99.3 50.1 180 0.6 0.1 0.1 177
  0.64 U
 48 Mix 30 64 36(56) 99.5 47.6 174 0.6 0.1 0.1 182
 47 Only 28 62 0(0) 98.0 58.7 174 0.8 0.2 0.1 176
  0.76 U
 47 30 30 66 30(45) 98.1 57.2 165 0.8 0.1 0.0 175
  0.64 U
 47 60 29 70 59(84) 98.0 55.5 167 0.9 0.1 0.0 175
  0.64 U
 47 Only 28 73 73(100) 98.4 52.8 167 0.8 0.1 0.0 175
  0.64 U
 47 Mix 28 65 29(45) 97.9 55.7 171 0.9 0.1 0.0 173
 36 Only 28 51 0(0) 96.2 57.3 176 0.5 0.1 0.0 180
  0.76 U
 36 30 29 55 29(53) 97.3 57.4 175 0.5 0.2 0.1 184
  0.64 U
 36 60 28 60 58(97) 96.4 61.7 176 0.5 0.1 0.0 180
  0.64 U
 36 Only 28 60 60(100) 96.5 56.5 176 0.5 0.2 0.1 180
  0.64 U
 36 Mix 30 55 26(47) 96.7 59.8 180 0.5 0.1 0.0 180
 29 Only 26 44 0(0) 96.0 56.8 170 0.4 0.2 0.0 177
  0.76 U
 29 30 25 49 29(59) 96.3 60.7 170 0.4 0.2 0.1 183
  0.64 U
 29 60 26 52 52(100) 96.0 56.8 170 0.4 0.2 0.0 177 
  0.64 U
 29 Only 28 53 53(100) 98.3 64.6 170 0.4 0.2 0.1 177 
  0.64 U
 29 Mix 27 47 20(43) 96.7 60.9 168 0.4 0.2 0.1 182
 20 Only 17 33 0(0) 98.3 57.4 181 0.8 0.1 0.0 176
  0.76 U
 20 30 18 38 30(79) 96.7 58.5 181 0.8 0.0 0.0 173
  0.64 U
 20 60 18 38 38(100) 98.1 58.7 176 0.8 0.0 0.0 174
  0.64 U
 20 Only 18 38 38(100) 97.3 54.2 176 0.8 0.1 0.0 174
  0.64 U
 20 Mix 18 36 18(50) 97.0 60.0 181 0.8 0.1 0.0 176
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A. Activities 0.32 u and 0.51 u 
Note that for any one case in Scenario I, Study 1 (Table 3), the target volume receiving 100% of 
the prescribed dose (V100
Prostate ) is within 2.3 percentage points for every plan and always above 
the clinically desirable 95%. The D90
Prostate  for all plans hovers around 120% of the prescription 
dose. This is to be expected when evaluating the preplan dosimetry as opposed to the post-plan 
dosimetry.(2,3) 
Also note that the V120
Urethra  is always below the clinically acceptable value of 1.0 cm3. Study 2 
under this scenario shows the effect of removing the per-needle penalty compared to Study 1, 
which preserves it. Note that the effect of removing the needle penalty is to increase the number 
of needles and obtain a slight increase in target coverage. Comparing Table 3 with Table 4 (and 
Table 5 with Table 6 in Scenario II) shows the effect of the per-needle penalty. In general, this 
penalty allows for a decrease in the number of needles needed independent of the hybrid status 
of the plan. It is interesting to note that, even in the case where the per-needle penalty is turned 
on (Tables 3 and 5), the plans generated with an unrestricted mix of seeds still preferred using 
some partial-activity seeds. For the studies with the per-needle penalty turned on, the number 
of needles recommended for each implant is consistent with the number of needles routinely 
used for actual implants performed at our clinic. 
B. Activities 0.64 u and 0.76 u 
The results are similar in Scenario II for both Study 1 (Table 5) and Study 2 (Table 6) across 
all plans. It is clear from these results that it is possible to achieve clinically acceptable dose 
distributions with hybrid plans that incorporate different-activity seeds. Across all four studies 
of each of the five patients, there is no evidence that the prostate size (which ranges from 20 
to 48 cc) has an effect on the dosimetry of the hybrid plans. 
Fig. 2. Scenario II, Study 1: Isodose lines for one slice of the 48 cm3 prostate. Isodose lines (outside in) are 50% (purple), 
100% (red), 125% (orange), 150% (yellow), 150% (black).
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Studies were performed on the geometric distribution of each seed type. The density of seeds 
as a function of distance from the center of mass of the prostate was examined. The prostate was 
divided in octants with the origin placed at the center of the prostate∫, and the density of seeds 
in each octant was evaluated. No correlation was found between seed location and seed type. 
A final study was performed in order to determine whether the optimized configuration of 
seed types is independent of the initial configuration. The initial configuration of seed types was 
set to be all of one activity or the other (as opposed to randomly chosen for each seed position, 
as was done in the main studies). The plans were then optimized requesting an unrestricted mix 
of the two seed types. The final configuration was found to have no correlation to the initial 
configuration of seed types. 
c. cPu time 
Table 7 shows the time needed to process the optimization in Scenario I Study 1 (all studies 
had similar results). The baseline IPSA(8,9,10,11) optimization for a single-activity varies from 
51–155 s. The hybrid optimization incorporates an increase in the degrees of freedom that must 
be probed, so an increase in optimization time is expected. The increase in optimization time 
varies from 17%–35%; however, this translates into only a 16–37 s increase in real time. Thus, 
the optimization time is still on the order of two minutes for all cases. Our clinical protocol 
for the baseline optimization uses a factor of five fewer iterations than used in this study. The 
optimizations were stable after a two-fold increase in the number of iterations over the clinical 
baseline; so the times listed here should be considered an upper limit which can be reduced 
without any clinically noticeable loss in plan quality by a factor of 2. 
Table 7. Scenario I; Study 1. CPU time required for optimization using a MacBook Pro running Mac OS 10.5.5 with 
a 2.33 GHz Intel Core 2 Duo processor and 3 GB RAM. On average there is a 25% increase in CPU time needed 
for the hybrid plan optimization; however, in real time this only amounts to at most about an 26-second increase in 
optimization time. This can be further reduced by a factor of two when implemented on a clinical system where fewer 
iterations are needed than in this proof of hypothesis study.
 Plan Type CPU Time for Each Optimization 48 cm3 47 cm3 36 cm3 29 cm3 20 cm3
Only 0.51 U 90 s 118 s 100 s 85 s 51 s
30 0.32 U 104 s 151 s 135 s 110 s 68 s
60 0.32 U 106 s 155 s 131 s 112 s 67 s
Only 0.32 U 97 s 125 s 104 s 90 s 51 s
Pure Hybrid 100 s 144 s 122 s 102 s 61 s
Max Increase (s) 16 s 37 s 35 s 27 s 17 s
Max Increase (%) 17% 24% 35% 24% 25%
IV. dIScuSSIon
As noted in the Introduction, the effect of the radioactive decay half-life can have an impact 
on the usability of seeds more than a week old. With activity reductions on the order of 40% 
after one week (Table 1), it is necessary to incorporate this change in activity into the planning 
workflow. In and of itself, this is not a problem since it is relatively simple to calculate the cur-
rent activity of the seeds available and build a treatment plan accordingly. But this only works 
if there are enough seeds to accommodate an entire implant. If there are fewer partial-activity 
seeds than is required for the implant, the partial-activity seeds are useless; the plan must be 
discarded and a new plan using full-activity seeds must be generated. 
∫ Since the prostate is generally of a regular geometry, this was defined by the intersection of the sagittal-, 
coronal- and transverse-bisecting planes.
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First and foremost, it is clear from Tables 3–6 that there is no degradation of plan quality 
when using partial activity seeds — both coverage of the target and sparing of the urethra are 
stable across plans. Given that plan quality is preserved, this algorithm would save both time 
(by eliminating the possibility that a plan with too many partial-activity seeds must be dis-
carded) and money (by allowing for the use of any inventory of partial-activity seeds). Since 
the algorithm includes input parameters to allow the user to chose a specific number of partial 
activity seeds, this method will work for any number of partial activity seeds.
 
A. Post-implant dosimetry 
From a clinical perspective, a challenging element of implementing the method presented in this 
work is calculating the real dose delivered to the patient due to the actual (rather than planned) 
implant. Since there is inherent seed placement error for PPI procedures, a post-implant dose 
calculation is used to assess the potential efficacy of the implant. 
It has been standard practice via the recommendations of the Radiation Therapy Oncology 
Group (RTOG) for this procedure(18,19) to obtain a one-month, post-implant CT of the patient, 
digitize the seeds, contour the organs and calculate the actual dose delivered. This may not be 
sufficient in hybrid cases since there are visually identical seeds with different activities — 
these must be identified. Thus it is necessary to create a one-to-one map between the planned 
seed positions and the actual positions. 
This procedure may be complicated by changes in the target volume and shape during the 
intervening one month between delivery and post-implant imaging. However, a recent trend(20) in 
PPI procedure is to obtain the post-implant CT immediately after the implant procedure (rather 
than after one month). This would mitigate the difficulties in seed matching which stem from 
debulking and edema. Obtaining the post-implant CT immediately after the procedure still would 
not account for the uncertainty inherent in placing seeds, but recent advances in post-implant 
seed identification show that a one-to-one map can be generated. Brunet-Benkhoucha et al.(21) 
have shown that with only seven X-ray images taken with a cone-beam system subtending a 
60° arc, seed detection rates of 96.7%, false negative rates of 3.3%, and false positive rates of 
2.7% can be achieved. This is done by locating seeds to 0.4 ± 0.4 mm in 3D space, and resulted 
in uncertainties in D90
Prostate  and V100
Prostate  of 1.5% and 0.3%, respectively. 
V. concLuSIonS
An optimization algorithm that can generate hybrid brachytherapy plans was developed. Five 
previously-treated PPI patients with a range of prostate volumes from 20 to 48 cm3 were chosen 
and reoptimized using the hybrid-activity PPI optimization. These multi-activity hybrid plans 
were equal in quality (as measured by the standard dosimetric indices) to plans with seeds of a 
single activity. Potential gains achievable by using different radionuclides have recently been 
explored in the literature; but, since the efficacy of incorporating the BED is still hotly debated 
in the community, we have focused on the multi-activity hybrid plans. Despite the expanded 
search space, optimization times for these studies were still under two minutes on a modern 
day laptop and can be reduced to below one minute in a clinical setting. With the typical cost 
of a set of PPI seeds on the order of thousands of dollars, it is possible to reduce the cost of 
brachytherapy treatments by allowing for easier use of seeds left over from a previous patient 
or unused due to a cancelled or postponed treatment. 
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